Pfizer (PFE) Stock Hits 52-Week High as Earnings Beat and Legal Win Land
TLDR
- Pfizer hit a new 52-week high of $29.09 on Tuesday, last trading at $28.75
- Q2 2026 earnings beat estimates: EPS of $0.77 vs $0.68 expected, revenue of $15.03B vs $14.42B expected
- Pfizer raised its full-year 2026 revenue outlook following the earnings beat
- The company settled over 6,000 federal Depo-Provera lawsuits, removing a major legal overhang
- Consensus analyst rating remains “Hold” with an average price target of $28.28
Pfizer hit a new 52-week high of $29.09 on Tuesday, with the stock last trading at $28.75. That puts the stock up roughly 20% year-to-date, a strong run for a company that has spent the better part of two years navigating the post-COVID revenue hangover.
Volume on the day came in at over 8.3 million, above typical levels, suggesting renewed investor interest.
The move comes on the back of a solid Q2 2026 earnings report. Pfizer posted adjusted EPS of $0.77, beating the Wall Street consensus of $0.68 by $0.09. Revenue hit $15.03 billion, topping expectations of $14.42 billion.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
